

PATENT

Attorney Docket No. 03804.1129-00000

RPR Docket No. EX93019-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:

U.S. Patent No. 5,837,531

Issued: November 17, 1998

Inventors: Jean-Francois DEDIEU et al.

Reissue Serial No.: Unassigned

Reissue Application Filed: August 31, 2000

For: RECOMBINANT ADENOVIRUSES FOR
GENE THERAPY IN CANCERS

Group Art Unit: Unassigned

Examiner: Unassigned

ATTN.: BOX REISSUE

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

**CONSENT OF ASSIGNEE, OFFER TO SURRENDER
ORIGINAL PATENT, POWER OF ATTORNEY,
AND STATEMENT UNDER 37 C.F.R. § 3.73(b)**

U.S. Patent No. 5,837,531 is assigned to Aventis Pharma S.A., formerly Rhône-Poulenc Rorer, S.A., as assignee of the entire right, title and interest in said patent by virtue of an assignment from Jean-Francois DEDIEU, Aude LE ROUX, and Michel PERRICAUDET ("the Inventors") to Rhône-Poulenc Rorer, S.A. recorded at Reel 007974, Frame 0407. Copies of these papers are attached.

Aventis Pharma S.A., formerly Rhône-Poulenc Rorer, S.A., hereby consents to the accompanying application for reissue of U.S. Patent 5,837,531.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Reissue Application of U.S. Patent No. 5,837,531
Attorney Docket No. 03804.1129-00000
RPR Docket No. EX93019-US

Aventis Pharma S.A., formerly Rhône-Poulenc Rorer, S.A., hereby offers to surrender U.S. Patent 5,837,531, when the reissue application is otherwise in condition for allowance.

Aventis Pharma S.A., formerly Rhône-Poulenc Rorer, S.A., hereby grants power of attorney to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilley, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr.,

Reissue Application of U.S. Patent No. 5,837,531
Attorney Docket No. 03804.1129-00000
RPR Docket No. EX93019-US

Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanhon Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33,921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; David A. Manspeizer, Reg. No. 37,540; and Timothy B. Donaldson, Reg. No. 43,592 both jointly and separately as their attorneys with full power of substitution and revocation to prosecute this application for reissue and to transact all business in the Patent and Trademark Office connected therewith, and to receive the reissued Letters Patent.

Reissue Application of U.S. Patent No. 5,837,531
Attorney Docket No. 03804.1129-00000
RPR Docket No. EX93019-US

Please send all future correspondence concerning this application to Finnegan,
Henderson, Farabow, Garrett & Dunner, L.L.P. at the following address:

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
1300 I Street, N.W.,
Washington, D.C. 20005-3315

The undersigned, whose title is supplied below, is empowered to sign on behalf of the
assignee.

I hereby declare that all statements made herein of my own knowledge are true and that
all statements made on information and belief are believed to be true; and further that these
statements are made with the knowledge that willful false statements and the like so made are
punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States
Code and that such willful false statements may jeopardize the validity of the application or any
patent issuing thereon.

Date

July 5, 2000

Signature



ROXANE DERNONCOUR

Name

AVENTIS PHARMA S.A.
PATENT ATTORNEY

Title

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000